Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 6, 2005, Pages 249-257

  Shayeganpour, Anooshirvan ^a   Jun, Andrew S ^b   Brocks, Dion R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b East LA Doctor's Hospital   (United States)

Author keywords

Antiarrhythmic drugs; Lipoproteins; Protein binding

Indexed keywords

AMIODARONE; ARACHIS OIL; CHOLESTEROL; LIPID; LIPOPROTEIN; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; FOOD DRUG INTERACTION; HYPERLIPIDEMIA; LIPID DIET; NONHUMAN; RAT; SIMULATION; SINGLE DRUG DOSE;

AMIODARONE; ANIMALS; AREA UNDER CURVE; BLOOD PROTEINS; DIETARY FATS; HYPERLIPIDEMIAS; LIPOPROTEINS; LIVER; MALE; MODELS, ANIMAL; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY;

EID: 25144456186     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.457     Document Type: Article

References (37)

1. Lucchesi BR. Antiarrhythmic drugs. In Cardiovascular Pharmacology, Antoaccio MJ (ed.). 3 edn. Raven: New York, 1990; 369-483.
2. Nattel S, Talajic M. Recent advances in understanding the pharmacology of amiodarone. Drugs 1988; 36: 121-131.
3. Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC. Amiodarone: what have we learned from clinical trials? Clin Cardiol 2000; 23: 73-82.
4. Naccarelli GV, Wolbrette DL, Patel HM, Luck JC. Amiodarone: clinical trials. Curr Opin Cardiol 2000; 15: 64-72.
5. Kerstein J, Soodan A, Qamar M, et al. Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: The GAP study. Chest 2004; 126: 716-724.
6. Klein H, Auricchio A, Reek S, Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999; 83: 91D-97D.
7. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
8. Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther 2000; 67: 642-652.
9. Thummell KE, Shen DD. Appendix II. Design and optimization of dosage regimens: Pharmacokinetic data. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Hardman JG, Limbird LE, Goodman Gilman A (eds). 10th edn. McGraw-Hill: New York, 2001; 1917-2023.
10. Wyss PA, Moor MJ, Bickel MH. Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. J Pharmacol Exp Ther 1990; 254: 502-507.
11. Kharidia J, Eddington ND. Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. Biopharm Drug Dispos 1996; 17: 93-106.
12. Talajic M, DeRoode MR, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation 1987; 75: 265-271.
13. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984; 9: 136-156.
14. Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 2001; 52 Suppl 1: 21S-34S.
15. Mason JW. Amiodarone. N Engl J Med 1987; 316: 455-466.
16. Lalloz MR, Byfield PG, Greenwood RM, Himsworth RL. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J Pharm Pharmacol 1984; 36: 366-372.
17. Ginsberg HN, Arad Y, Goldberg IJ. Pathophysiology and therapy of hyperlipidemia. In Cardiovascular Pharmacology, Antoaccio MJ (ed.). 3 edn. Raven: New York, 1990; 485-513.
18. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003; 169: 921-924.
19. Meng X, Mojaverian P, Doedee M, et al. Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am J Cardiol 2001; 87: 432-435.
20. Lefebvre M, Aumais C, Tanguay JF, et al. Influence of food on the pharmacokinetics of amiodarone: Two bioequivalence (BE) studies show increased absorption with possible clinical ramifications. AAPS PharmSci 1999; Suppl.: Abstract 4046.
21. Andreasen F, Agerbaek H, Bjerregaard P, Gotzsche H. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 1981; 19: 293-299.
22. Brocks DR, Wasan KM. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. J Pharm Sci 2002; 91: 1817-1826.
23. Humberstone AJ, Porter CJ, Edwards GA, Charman WN. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J Pharm Sci 1998; 87: 936-942.
24. Wout ZG, Pec EA, Maggiore JA, et al. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenter Sci Technol 1992; 46: 192-200.
25. Schuhmacher J, Buhner K, Witt-Laido A. Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 2000; 89: 1008-1021.
26. Jun AS, Brocks DR. High-performance liquid chromatography assay of amiodarone in rat plasma. J Pharm Pharm Sci 2001; 4: 263-268.
27. Shayeganpour A, Brocks DR. Joint assay of desethylamiodarone and amiodarone in rat plasma by high performance liquid chromatography. Abstract 42. J Pharm Pharm Sci 2003; 6: 160.
28. Gibaldi M, Perrier D. Pharmacokinetics. Dekker: New York, 1982.
29. Johnston TP, Palmer WK. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 1993; 46: 1037-1042.
30. Johnston TP. The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J Cardiovasc Pharmacol 2004; 43: 595-606.
31. Pec EA, Wout ZG, Johnston TP. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J Pharm Sci 1992; 81: 626-630.
32. Dumaswala R, Berkowitz D, Heubi JE. Adaptive response of the enterohepatic circulation of bile acids to extrahepatic cholestasis. Hepatology 1996; 23: 623-629.
33. Klaassen CD, Watkins JB, 3rd. Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol Rev 1984; 36: 1-67.
34. Knox R, Stein I, Levinson D, Tso P, Mansbach CM, 2nd. Effect of fat pre-feeding on bile flow and composition in the rat. Biochim Biophys Acta 1991; 1083: 65-70.
35. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
36. Riva E, Gerna M, Neyroz P, et al. Pharmacokinetics of amiodarone in rats. J Cardiovasc Pharmacol 1982; 4: 270-275.
37. Myung SW, Chang YJ, Min HK, et al. Characterization of amiodarone metabolites and impurities using liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom 2000; 14: 2046-2054.